Publications by authors named "Bart Spiessens"

Claim this Profile

Mentions over time

Mentions by platform

Video Views

1,129,283

Total Likes

22,778

Extended Reach

2,238,248

Social Features

286
S
Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19.
Jerald Sadoff, Glenda Gray, An Vandebosch, Vicky Cárdenas, Georgi Shukarev, Beatriz Grinsztejn, Paul A Goepfert, Carla Truyers, Hein Fennema, Bart Spiessens

June 2021

Videos about Article: user user user 1

4 10 282 15 214 2

View All Article and Social Media Activity
A
Adopting the estimand framework in prophylactic vaccine trials.
Francois Beckers, Naveen Karkada, Ye Yang, John Scott, Lei Huang, Bart Spiessens

Vaccine· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A retrospective global study of the prevalence of O-serotypes of invasive disease in patients admitted to tertiary care hospitals.
Jeroen Geurtsen, Joachim Doua, Luis Martinez-Martinez, Patricia Ibarra de Palacios, Jeff Powis, Bart Spiessens

Epidemiol Infect· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety, reactogenicity, and immunogenicity of different doses of 10-valent Extraintestinal Pathogenic Escherichia Coli (ExPEC10V) bioconjugate vaccine (VAC52416) in healthy Japanese adults aged 60-85 years in a randomized, double-blind, phase 1 study.
Miwa Haranaka, Atsushi Momose, Yoshikazu Nakayama, Yuki Saito, Bart Spiessens

J Infect Chemother· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Epidemiology of invasive disease in adults in England, 2013-2017.
Maxim Blum, Jeroen Geurtsen, Eva Herweijer, Michal Sarnecki, Bart Spiessens

Epidemiol Infect· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A microbiological and genomic perspective of globally collected Escherichia coli from adults hospitalized with invasive E. coli disease.
Enya Arconada Nuin, Tuba Vilken, Basil Britto Xavier, Joachim Doua, Brian Morrow, Bart Spiessens

J Antimicrob Chemother· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Unbiased identification of risk factors for invasive Escherichia coli disease using machine learning.
Erik Clarke, Christel Chehoud, Najat Khan, Bart Spiessens, Jan Poolman

BMC Infect Dis· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical presentation and antimicrobial resistance of invasive Escherichia coli disease in hospitalized older adults: a prospective multinational observational study.
Joachim Doua, Jesús Rodríguez-Baño, Rachel Froget, Padma Puranam, Oscar Go, Bart Spiessens

Infection· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomized phase 1/2a trial of ExPEC10V vaccine in adults with a history of UTI.
Carlos A Fierro, Michal Sarnecki, Bart Spiessens, Oscar Go, Tracey A Day

NPJ Vaccines· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Feasibility of tracking invasive Escherichia coli disease among older adults in a community setting: A prospective observational study.
Joachim Doua, Miquel Ekkelenkamp, Theo Verheij, Oscar Go, Stephen Ruhmel, Bart Spiessens

Eur J Clin Microbiol Infect Dis· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Harmonizing the collection of solicited adverse events in prophylactic vaccine clinical trials.
Brigitte Cheuvart, Bart Spiessens, Roy van Heesbeen, Derchieh Hung, Coralie Andrade

Expert Rev Vaccines· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety, Reactogenicity, Immunogenicity, and Dose Selection of 10-Valent Extraintestinal Pathogenic Bioconjugate Vaccine (VAC52416) in Adults Aged 60-85 Years in a Randomized, Multicenter, Interventional, First-in-Human, Phase 1/2a Study.
Carlos A Fierro, Michal Sarnecki, Joachim Doua, Bart Spiessens, Oscar Go

Open Forum Infect Dis· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Global Distribution of O Serotypes and Antibiotic Resistance in Extraintestinal Pathogenic Escherichia coli Collected From the Blood of Patients With Bacteremia Across Multiple Surveillance Studies.
Eveline Weerdenburg, Todd Davies, Brian Morrow, Aldert L Zomer, Peter Hermans, Bart Spiessens

Clin Infect Dis· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Distribution of extraintestinal pathogenic Escherichia coli O-serotypes and antibiotic resistance in blood isolates collected from patients in a surveillance study in Japan.
Tetsuya Matsumoto, Hiroshige Mikamo, Hiroki Ohge, Katsunori Yanagihara, Eveline Weerdenburg, Bart Spiessens

J Infect Chemother· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Non-human primate to human immunobridging demonstrates a protective effect of Ad26.ZEBOV, MVA-BN-Filo vaccine against Ebola.
Viki Bockstal, Maarten Leyssen, Dirk Heerwegh, Bart Spiessens, Cynthia Robinson

NPJ Vaccines· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Final Analysis of Efficacy and Safety of Single-Dose Ad26.COV2.S.
Jerald Sadoff, Glenda Gray, An Vandebosch, Vicky Cárdenas, Georgi Shukarev, Bart Spiessens

N Engl J Med· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Protocol for a phase 3 trial to evaluate the effectiveness and safety of a heterologous, two-dose vaccine for Ebola virus disease in the Democratic Republic of the Congo.
Deborah Watson-Jones, Hugo Kavunga-Membo, Rebecca F Grais, Steve Ahuka, Natalie Roberts, Bart Spiessens

BMJ Open· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Epidemiology and O-Serotypes of Extraintestinal Pathogenic Disease in Patients Undergoing Transrectal Ultrasound Prostate Biopsy: A Prospective Multicenter Study.
Steven Rosenberg, Marc Bonten, Wouter Haazen, Bart Spiessens, Darren Abbanat

J Urol· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reply by Authors.
Steven Rosenberg, Marc Bonten, Wouter Haazen, Bart Spiessens, Darren Abbanat

J Urol· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nonhuman primate to human immunobridging to infer the protective effect of an Ebola virus vaccine candidate.
Ramon Roozendaal, Jenny Hendriks, Thierry van Effelterre, Bart Spiessens, Liesbeth Dekking

NPJ Vaccines· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characterization of Escherichia coli isolates potentially covered by ExPEC4V and ExPEC10V, that were collected from post-transrectal ultrasound-guided prostate needle biopsy invasive urinary tract and bloodstream infections.
Elie Saade, Stefan Gravenstein, Curtis J Donskey, Brigid Wilson, Bart Spiessens

Vaccine· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Th1/IFNγ Gene Signature Is Prognostic in the Adjuvant Setting of Resectable High-Risk Melanoma but Not in Non-Small Cell Lung Cancer.
Benjamin Dizier, Andrea Callegaro, Muriel Debois, Brigitte Dreno, Peter Hersey, Bart Spiessens

Clin Cancer Res· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and immunogenicity of a vaccine for extra-intestinal pathogenic Escherichia coli (ESTELLA): a phase 2 randomised controlled trial.
Robert W Frenck, John Ervin, Laurence Chu, Darren Abbanat, Bart Spiessens

Lancet Infect Dis· June 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
MAGE-A3 immunotherapeutic as adjuvant therapy for patients with resected, MAGE-A3-positive, stage III melanoma (DERMA): a double-blind, randomised, placebo-controlled, phase 3 trial.
Brigitte Dreno, John F Thompson, Bernard Mark Smithers, Mario Santinami, Thomas Jouary, Bart Spiessens

Lancet Oncol· July 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Testing interaction between treatment and high-dimensional covariates in randomized clinical trials.
Andrea Callegaro, Bart Spiessens, Benjamin Dizier, Fernando U Montoya, Hans C van Houwelingen

Biom J· July 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis